包皮过长或包茎患者的性功能状况与心理状态关系的研究

目的:通过分析泌尿男科门诊包皮过长或包茎患者的性功能状况与心理状态,探讨性功能障碍与心理异常之间的相互关系。方法:随机选择包皮过长或包茎患者216例,问卷调查患者的一般情况、中国早泄患者性功能评价表、国际勃起功能指数问卷、症状自评量表。调查研究患者的早泄与勃起功能障碍情况,心理状态抑郁、焦虑等症状,统计其发生率,分析各症状间的相互关系。85例健康男性志愿者为正常对照组。结果:病例组的症状自评量表总分、躯体化因子分、强迫症状因子分、抑郁因子分、焦虑因子分、其他因子分明显高于正常对照组(P<0.05)。相关分析显示:早泄评分与症状自评量表总分、躯体化因子分、强迫症状因子分、人际关系敏感因子分、抑郁因子分、焦虑因子分及其他因子分有显著相关性。勃起功能障碍评分与症状自评量表总分及各项因子分无相关性。结论:泌尿男科门诊包皮过长或包茎患者的心理健康水平较差,早泄与心理状态存在相互影响。     

勃起功能障碍的诊断和疗效评估相关问卷

勃起功能障碍(ED)诊断和治疗效果的评估过程中,患者问卷是一种常用评估工具,其种类和数量也日渐增多。本文介绍了几种常见且有效的ED问卷,包括国际勃起功能问卷(IIEF)、男性性健康量表(SHIM)、IIEF勃起功能专项评分(IIEF-EF)、勃起硬度分级(EHGS)、自尊心及性关系问卷(SEAR)、勃起功能障碍治疗满意度量表(ED-ITS),以及勃起质量问卷(QEQ)、治疗满意度评分(TSS)、心理及人际关系评分(PAIRS)、性体验问卷(SEX-Q),并对其临床针对性做了讨论。     

慢性前列腺炎与性功能障碍的调查分析

目的 :调查慢性前列腺炎患者性功能障碍的患病率及其与年龄、病程的关系。　方法 :对 2 0 0 0例患者进行了问卷调查 ,内容包括 :①年龄、身高、体重、职业、病程、治疗情况等 ;②国际前列腺炎症状评分指数表 (NIH CPSI) ;③勃起功能国际指数问卷 5 (IIEF 5 )。　结果 :176 8份调查表有效 (88.4 % )。慢性前列腺炎患者性功能障碍的患病率为 4 9.0 % ,其中 ,早泄占 2 6 .4 % ,勃起功能障碍占 14 .9% ,早泄合并勃起功能障碍占 7.7%。　结论 :慢性前列腺炎患者性功能障碍的患病率较高 ,患病率与患者年龄及病程呈负相关。     

非特异性下腰痛与男性性功能障碍的相关性分析

目的：研究非特异性下腰痛与男性性功能障碍的相关性。方法：对241例男性非特异性下腰痛患者和110例男性健康对照者进行研究。采用国际勃起功能指数和早泄诊断工具评价性功能,并与患者的年龄和病程长短进行相关性评估。结果：非特异性下腰痛患者的性功能障碍发生率为32.37%,健康对照者发生率为12.73%。年龄越大、病程越长的男性,性功能障碍患病率越高。结论：男性非特异性下腰痛患者的性功能障碍患病率较高,明显高于健康对照者。在非特异性下腰痛患者的日常护理和治疗中应增加性治疗和性管理。     

勃起功能障碍患者及其性伴侣治疗满意度量表(TSS)介绍

勃起功能障碍(erectile dysfunction,ED)是一种常见疾病,有研究表明约5%~20%的男性患有中至重度ED,有关勃起功能障碍患者治疗效果的评估多以自评报告为主,关于评估疗效的各种问卷较多,但能被人们接受的、较为全面的问卷较少。勃起功能障碍治疗满意度调查问卷手册(Erectile Dysf     

他达拉非、西地那非和伐地那非治疗6个月后的疗效和患者满意度：勃起功能障碍观察性研究（EDOS）

EDOS是一项在全欧开展，旨在评估勃起功能障碍（ED）男性患者在实际临床中接受6个月他达拉非、枸橼酸西地那非（西地那非）或盐酸伐地那非（伐地那非）治疗后健康状况的研究。研究中药物的疗效和患者满意度的评估指标为一些已经得到确认的问卷，如全球评估问卷（GAQ）、国际勃起功能指数（IIEF）、     

应用新的治疗满意度量表来评估ED患者及其性伴侣对伐地那非治疗的满意度

治疗满意度量表(TSS)是为评估男性勃起功能障碍(ED)患者及其性伴侣对ED治疗的满意度而制订的一个新量表。该自我报告式的调查问卷由四大部分组成:未治疗期的患者,治疗期的患者,未治疗期患者的性伴侣,以及治疗期患者的性伴侣。对以下6个方面进行评估:自信心、勃起的容易度、对勃起功能的满意度、性快感、对性高潮的满意度以及治疗满意度。TSS量表已经过多国有效性检验和心理学测验,被证明能可靠评价患者及其伴侣对ED治疗的满意度。在最近完成的一项双盲、多中心、平行组、灵活剂量的临床试验中,应用这个新的TSS量表比较了ED患者及其伴侣对伐地那非和安慰剂治疗的满意度。结果发现,伐地那非能显着改善勃起功能以及ED患者和伴侣的自信心、感知到的勃起容易度、性快感、对勃起功能、高潮和药物治疗的满意度。     

西地那非治疗前列腺癌放疗后勃起功能障碍的前瞻性研究

勃起功能障碍（ED）是前列腺癌患者接受外照射治疗后常见的晚期并发症。为了解西地那非治疗此类ED患者的有效性和安全性，Weber等进行了一项包括35例患者的前瞻性研究。采用基于国际性功能指数问卷（IISF）的25分量表每周评估勃起功能，在此期间患者每周口服100mg西地那非，连续6周。     

配偶干预对男性勃起功能障碍患者的治疗作用

目的探讨配偶干预对男性勃起功能障碍患者的治疗作用。方法选取2015年6月至2017年10月就诊于我院的158例勃起功能障碍患者,随机分为对照组和观察组,对照组患者给予药物治疗并辅助相应的心理治疗,观察组患者在给予药物治疗和心理干预的同时,要求配偶根据既定的实验方案参与治疗。治疗前后分别采用IIEF勃起功能专项评分、勃起功能障碍治疗满意度量表、自尊心及性关系问卷来评价干预效果。结果治疗前,两组勃起功能专项评分、勃起功能障碍治疗满意度,自尊心、总体关系满意度与性关系满意度评分比较,差异无统计学意义(均P 0. 05);治疗后,两组各项评分均较治疗前有所提升,观察组各项指标显著优于对照组(均P 0. 01)。结论配偶干预可有效改善男性勃起功能障碍患者的治疗效果,提高患者治疗满意度,提升患者自尊心以及性关系满意度。     

西地那非治疗男性腹膜透析患者ED的有效性研究

肾功能不全严重影响患者的性功能，在透析治疗的男性患者中，勃起功能障碍（ED）有着较高的发病率。治疗ED的一线药物西地那非对于此类患者是否有效且安全呢？MahonA等人对16名腹膜透析的ED患者进行了为期8周的前瞻性研究，评价了西地那非治疗男性腹膜透析患者勃起功能障碍的安全性和有效性。研究中，以国际勃起功能评分和整体评价问卷评估治疗的有效性，运用多普勒超卢评价阴茎动脉供血，并且记录所有副作用。结果显示，勃起功能在两地那非组较安慰剂组有显著改善，治疗后，性交满意度和总体满意度也较治疗前明显改善，根据整体评价问卷结果，75％的患者认为西地那非治疗改善了勃起功能。仅有1名患者报告出现头痛的副作用，且在使用西地那非第三次后消失。     

Patient satisfaction with testosterone supplementation for the treatment of erectile dysfunction

The long-term efficacy of testosterone supplementation for erectile dysfunction was evaluated using standardized questionnaires and differences between testosterone delivery systems analyzed. Forty-four patients receiving parenteral depo-testosterone, Testoderm scrotal patches, or Testoderm-TTS nonscrotal patches were evaluated with the Erectile Dysfunction Inventory of Treatment Satisfaction and International Index of Erectile Function questionnaires. Global questions regarding libido, energy, and improved erections demonstrated a significantly better response with depo-testosterone and Testoderm-TTS nonscrotal patches as compared to Testoderm scrotal patches. Testoderm-TTS nonscrotal patches and depo-testosterone resulted in significantly higher overall treatment satisfaction (p <.001), confidence in ability to engage in sexual activity (p <.001), and total Erectile Dysfunction Inventory of Treatment Satisfaction and International Index of Erectile Function scores (p <.001). Testoderm-TTS nonscrotal patches were significantly better than depo-testosterone with regard to satisfaction with sexual intercourse (International Index of Erectile Function question 5, p <.05). Testosterone replacement improved the quality of erections and level of libido in patients with erectile dysfunction. Treatment delivery systems appear to impact the success of therapy.     

An assessment of patient-reported outcomes for men with erectile dysfunction: Pfizer's perspective

Patient-reported outcomes (PROs) for men with erectile dysfunction (ED) have blossomed in the published literature and at professional conferences. These outcomes have been central to study the science of ED itself and to evaluate efficacy of treatment for men with ED. In this review article we highlight and distinguish among seven key PROs: the International Index of Erectile Function, for sexual function including erectile function; the Sexual Health Inventory for Men (SHIM), for diagnosis of ED; the Quality of Erection Questionnaire, for satisfaction with quality of erections; the Erectile Dysfunction Inventory of Treatment Satisfaction, for personal evaluation of treatment received; the Self-Esteem And Relationship questionnaire, for emotional well-being; the Erection Hardness Score (EHS), for targeting erection hardness and the Sexual Experience Questionnaire, for erection (both function and quality), individual satisfaction and couples satisfaction. Depending on the purpose of the investigation, all seven PROs have merit for use in clinical trials and at least deserve consideration in clinical practice. The SHIM and the EHS, given their aims and brevity, deserve special consideration in clinical practice. As a unit these seven PROs complement and supplement each other. Which ones to choose in a particular undertaking depends on the objective or purpose of a given study. These PROs acknowledge that sexual dysfunction and its treatment have multiple dimensions. Each of these instruments represents a significant contribution to sexual medicine research and, when used judiciously and appropriately, can help to provide optimal patient care and management.     

意大利临床实践中的PDE5抑制剂治疗模式：“勃起功能障碍观测研究”的纵向数据

“勃起功能障碍观测研究”（Erectile Dysfunction Observational Study,EDOS）是一项为期6个月的多中心前瞻性研究,研究对象包括被要求开始接受治疗或改变治疗方式的ED病人。本研究旨在分析ED的治疗模式,并比较不同治疗模式的疗效。研究对象为到医院看病并诊断需要进行ED治疗的患者。他们接受ED治疗,并在治疗开始时、治疗3个月、6个月时回答来自IIEF（International Index of Erectile Function）,EDITS（Erectile Dysfunction Inventory of Treatment Satisfaction）,SF-PAIRS（Short Form of the Psychological and Interpersonal Relationship Scale）／nq卷的问题。医生可以给病人开出市场上现有的任何疗法,并可以在治疗过程中任何时间改变疗法。在完成为期6个月的分析的1338名病人中,有624人（47％）改变了疗法,714人（53％）一直接受最初诊断的疗法,其中接受治疗的病人持续接受一种疗法的比率显著高于接受西地那非或伐地那非治疗的病人。其它影响这一比率的变量包括性欲低下和ED。各种PDE-5抑制剂在效力、病人满意度、自信心、自发性等方面无显著差异。接受他达拉非治疗的病人的SF—PAIRS“时间相关”项的分数显著优于接受其它治疗的病人。结果显示现有的三种PDE-5抑制剂的临床实践和临床实验结果相似,但病人如果要终止或改变用药,他达拉非的风险较低。     

Responsiveness and minimum important differences for the erection quality scale

PURPOSE: We evaluated the responsiveness and treatment sensitivity of the Erection Quality Scale, and provided further psychometric validation of this scale. MATERIALS AND METHODS: An 8-week, placebo controlled, randomized clinical trial investigating the efficacy and safety of vardenafil in patients with erectile dysfunction was performed. The Erection Quality Scale, together with a number of other patient and partner questionnaires, was administered at a screening visit, at baseline, and weeks 4 and 8 of treatment. Erection Quality Scale responsiveness was investigated by evaluating treatment induced changes and modeling using ANCOVA. Internal consistency, convergent and discriminant validity, and minimum important difference of the Erection Quality Scale were also assessed. RESULTS: Efficacy evaluations demonstrated that the Erection Quality Scale was sufficiently responsive to differentiate the treatment benefits of vardenafil compared with placebo. Internal consistency for the Erection Quality Scale total score was similar across visits, with values high enough to suggest reliability of items included in the scale. Discriminant validity of the Erection Quality Scale total score was demonstrated, with a high correlation with the erectile function domain of the International Index of Erectile Function (0.88, p <0.0001) and negligible correlations with clinical measures assumed to be unrelated to erection quality. All Erection Quality Scale total score comparisons substantially exceeded the 5-point minimum important difference estimate. CONCLUSIONS: The Erection Quality Scale was responsive and internally consistent, and demonstrated convergent and discriminant validity. Furthermore, this instrument provided a unique contribution to the measurement of erection quality compared to the International Index of Erectile Function. This study provides strong evidence supporting the use of the Erection Quality Scale in clinical trials.     

平凉市中老年男性性功能调查报告

目的 调查平凉市中老年男性性欲低下、勃起功能障碍(erectile dysfunction,ED)、射精障碍的患病情况.方法 采用分层多阶段整群不等比例随机抽样方法,选择城区6个居委会和郊区20个行政村1539名年龄≥50岁男性作为调查对象,分别记录国际勃起功能问卷(IIEF-5)评分及男性性功能问卷(O'Leafy ...     

The psychological burden of premature ejaculation

PURPOSE: Premature ejaculation is characterized by short ejaculatory latency, inability to control ejaculation and resultant overall decreased sexual satisfaction for the man and his partner. Diagnostic criteria typically include aspects of psychological well-being. To motivate and justify treatment for premature ejaculation a more comprehensive understanding of its impact on men, their partners and their overall relationship is needed. MATERIALS AND METHODS: In a community based, observational study of 1,587 men and their female partners clinicians diagnosed premature ejaculation using Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision criteria. For purposes of this analysis this group was further restricted to subjects with a stopwatch measured intravaginal ejaculatory latency time of 2 minutes or less. Responses to the Premature Ejaculation Profile, Self-Esteem and Relationship questionnaire, Golombok-Rust Inventory of Sexual Satisfaction and Medical Outcomes Study SF-36 were compared between premature ejaculation and nonpremature ejaculation groups. Correlations between responses of men and partners were assessed for the Premature Ejaculation Profile and Golombok-Rust Inventory of Sexual Satisfaction. Correlations among patient reported measures enabled the assessment of independence of outcome variables. RESULTS AND CONCLUSIONS: Of 207 men who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision criteria 89 had an intravaginal ejaculatory latency time of 2 minutes or less. Lower levels of sexual functioning and satisfaction, and higher levels of personal distress and interpersonal difficulty were reported by men with premature ejaculation and their partners. In addition, men with premature ejaculation rated their overall quality of life lower than that of men without premature ejaculation. Consequently premature ejaculation has a significant psychological burden on men, their partners and the male/partner relationship.     

Is sildenafil citrate associated with an amelioration of the symptomatology of androgen decline in the aging male?

PURPOSE: We examined whether treatment of erectile dysfunction with sildenafil citrate is associated with amelioration of the symptomatology of androgen decline in the aging male, and whether this alters the endocrine pattern. MATERIALS AND METHODS: A double-blind, randomized, placebo controlled, crossover study with sildenafil citrate was conducted in 60 men (age range 47 to 75 years old) who presented with erectile dysfunction and screened positively for androgen decline in the aging male by the questionnaire of the same name. The patients were randomized to receive sildenafil citrate or placebo in a 1:1 ratio and were crossed over after 3 months of treatment for an additional 3 months. The evaluation included International Index Erectile Function and Aging Male Symptoms questionnaires, hormonal profiles, total testosterone, and bioavailable testosterone. RESULTS: A total of 40 patients completed the study. Compared to placebo, sildenafil citrate improved erectile function (52.7 +/- 2 vs 39 +/- 1.9, p <0.001) and Aging Male Symptoms score (33.5 +/- 1.3 vs 28.6 +/- 1.3, p <0.001) in the total group. Breakdown into hypogonadal and normal men showed that the International Index of Erectile Function score improved more in normal (Delta 18.5 +/- 3.6) than in hypogonadal men (Delta 6.7 +/- 2.7). There were no differences in improvement on the Aging Male Symptoms questionnaire between hypogonadal and normal men. No treatment changes were observed in total testosterone and bioavailable testosterone. CONCLUSIONS: In the total group of patients sildenafil citrate was associated with expected improvement in erectile function and in the Aging Male Symptoms questionnaire without any alteration in hormonal pattern. The available questionnaires for androgen decline in the aging male are not specific for the diagnosis of biochemical androgen decline in the aging male, although the suboptimal response to sildenafil citrate suggests the presence of hypogonadism.